13 results
DEF 14C
BGLC
BioNexus Gene Lab Corp
29 Feb 24
Information statement
5:16pm
-relation.
Employee, Officer and Director Hedging
The Company does not currently have a policy in place regarding the hedging of the Company’s
PRE 14C
BGLC
BioNexus Gene Lab Corp
26 Jan 24
Preliminary information
4:05pm
Conduct can be found on our website under “Investor Relation” at https://www.bionexusgenelab.com/investor-relation.
Employee, Officer and Director Hedging …
The Company does not currently have a policy in place regarding the hedging of the Company’s securities other than its Code of Ethics and Business
8-K
EX-4.1
BGLC
BioNexus Gene Lab Corp
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
WARRANT OR THE SECURITIES ISSUABLE HEREUNDER TO BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT OR CALL TRANSACTION THAT WOULD RESULT … or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective
8-K
EX-1.1
BGLC
BioNexus Gene Lab Corp
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any
424B4
BGLC
BioNexus Gene Lab Corp
21 Jul 23
Prospectus supplement with pricing info
3:37pm
or the Medicare contribution tax on net investment income;
U.S. expatriates;
persons holding our common stock as part of a straddle, hedging, constructive sale … stock issued upon exercise of the Underwriter Warrants may be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging
DEF 14C
x4fctj auh1ck9y669b
17 May 23
Information statement
9:07am
8-K
EX-10.5
0qa6rx2z4u5ur 027
30 Dec 20
Entry into a Material Definitive Agreement
2:09pm
- Prev
- 1
- Next